Gender differences low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real world patients
نویسندگان
چکیده
Abstract Background Monoclonal antibodies that inhibit the proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density lipoprotein cholesterol (LDLc) by 55%, regardless of baseline treatments, and are supposed to have a homogenous effect. We tested possible gender differences in large multicenter registry real-world patients treated with PCSK9 inhibitors. Methods Multicentre retrospective inhibitors from 14 different hospitals Spain. Before on-treatment LDLc was recorded as well medical clinical indication features. Results A total 562 were analysed, mean age 60.2 (9.6) years 79.2% males. Most frequent for inhibitor treatment established cardiovascular disease (CVD) >100 mg/dl (58.1%) followed familial hypercholesterolemia (23.4%) statin intolerance (18.5%). Indications other than CVD more women (53.3% vs. 39.1%; p=0.03). Women frequently ezetimibe (67.5% 50.6%; p=0.001) before treatment; although no use observed (78.6% 83.6%; p=0.93) whole cohort it significantly lower coronary heart (91.4% 98.9%; p=0.005). 148.7 (50.1) higher men (160.3 (59.3) 145.6 (47.0); Evolocumab initiated 318 (56.6%) patients; 229 (40.7%) alirocumab 75 mg 15 (2.7%) 150 mg. No drug or dose observed. Median time second blood determination 187.5 (IQR 101–242) days. Mean 66.7 (46.4) also (84.4 (58.6) 61.9 (41.3); p<0.001). reduction 54.7% but compared (57.0% 46.1%; p=0.0003). Higher reductions 2 indications (57.1% 47.3%; p=0.002). Moreover, vs among (58.9% 48.0%; p=0.04) Conclusions This multicentre highlights significant reduction. FUNDunding Acknowledgement Type funding sources: None.
منابع مشابه
Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.
OBJECTIVES We sought to evaluate the significance of high-density lipoprotein cholesterol (HDL-C) in the context of low low-density lipoprotein cholesterol (LDL-C). BACKGROUND Earlier studies support an inverse correlation between circulating HDL-C and coronary risk in patients with normal or elevated LDL-C. METHODS This study involved 4,188 patients attending the Palo Alto Veterans Adminis...
متن کاملRare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
BACKGROUND Screening of variants, related to lipid metabolism in patients with extreme cholesterol levels, is a tool used to identify targets affecting cardiovascular outcomes. The aim of this study was to examine the prevalence and characteristics of rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol (LDL-C) levels. METHODS Am...
متن کاملcholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, non–high-density lipoprotein cholesterol, or low-density lipoprotein particle concentration and guideline categories of low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol
International clinical practice guidelines on dyslipidemia emphasize the importance of matching the use and intensity of statin therapy with the absolute risk of atherosclerotic cardiovascular disease (CVD). Indeed, independent of the baseline level of dyslipidemia, patients who have entered the intervention arms of randomized clinical trials of statin therapy with similar absolute risks of CVD...
متن کاملBeyond Low-Density Lipoprotein Cholesterol
Recent clinical trials in patients with coronary artery disease (CAD) provide evidence that low-density lipoprotein cholesterol (LDL-C) levels should be lowered even further to prevent recurrent CAD. However, despite more aggressive interventions for lowering LDL-C levels, the majority of CAD events go undeterred, perhaps related to the fact that intervention was not started earlier in life or ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2021
ISSN: ['2634-3916']
DOI: https://doi.org/10.1093/eurheartj/ehab724.2589